 Schubert Jonckheer Kolbe LLP is investigating potential shareholder derivative claims on behalf of stockholders of Apyx Medical Corporation NASDAQ: APYX related to the companys statements regarding its December 2018 application to the U.S. Food and Drug Administration for expanded uses of Apyxs J-Plasma technologythe companys key growth product. 